<bill session="117" type="h" number="9321" updated="2023-08-15T15:45:20Z">
  <state datetime="2022-11-16">REFERRED</state>
  <status>
    <introduced datetime="2022-11-16"/>
  </status>
  <introduced datetime="2022-11-16"/>
  <titles>
    <title type="display">Independent Drug Value Assessment Act</title>
    <title type="short" as="introduced">Independent Drug Value Assessment Act</title>
    <title type="official" as="introduced">To amend the Public Health Service Act to provide for the development and publication of independent value assessments for drugs, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="S001175"/>
  <cosponsors>
    <cosponsor bioguide_id="N000002" joined="2022-11-16"/>
    <cosponsor bioguide_id="P000618" joined="2022-11-16"/>
  </cosponsors>
  <actions>
    <action datetime="2022-11-16">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-11-16" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-11-17">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-08-15T15:39:31Z" status="Introduced in House">Independent Drug Value Assessment Act

This bill requires the Office of the Assistant Secretary for Planning and Evaluation to contract with outside entities to conduct independent value assessments of approved drugs (i.e., economic analysis of the benefits to patients and the health care system).</summary>
</bill>
